Online inquiry

IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4045MR)

This product GTTS-WQ4045MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL36RN gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_012275.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26525
UniProt ID Q9UBH0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4045MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9403MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ13554MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ5466MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ15149MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA SYNT-001
GTTS-WQ9847MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ12379MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NEOD-001
GTTS-WQ1939MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ15918MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XOMA 052
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW